Target intelligence / Profile preview

Glutamate receptor ionotropic, delta-2 subunit (GRID2)

Target
GRID2
Molecular classification
Ion channel, Receptor, Ligand-gated ion channel, Ionotropic glutamate receptor (delta family)
01

Overview

Glutamate receptor ionotropic, delta-2 subunit (GRID2) is a member of the ionotropic glutamate receptor family, predominantly expressed in cerebellar Purkinje cells, where it is essential for synapse formation, synaptic plasticity, and motor coordination[1][2][3]. Unlike typical ionotropic glutamate receptors, GRID2 is an orphan receptor that does not directly respond to glutamate but can interact with glycine and D-serine, though channel gating requires the presence of additional synaptic proteins (cerebellin-1 and neurexin-1β)[1][2][3]. Dysfunction or mutation of GRID2 leads to neurodevelopmental disorders, especially forms of cerebellar ataxia, and the receptor has a key (but indirect) role in maintaining normal cerebellar circuitry and motor function. Structural and pharmacological studies confirm its role as a cation-selective ion channel within the subfamily of delta-type ionotropic glutamate receptors, but its pharmacology remains poorly explored, with no current clinical drugs specifically targeting GRID2[1][2][3].

Other names
GluD2GluRδ2GluR delta-2 subunitGLURD2SCAR18glutamate receptor ionotropic, delta-2glutamate receptor delta-2 subunitglutamate receptor, ionotropic, delta 2gluR delta-2 subunit
02

Mechanism of action

Antagonism of delta-2-containing ionotropic glutamate receptors (for the compounds above; however, pharmacological targeting in clinical use is unestablished)

03

Biological functions

Synaptogenesis (formation of synapses)Synaptic plasticity (modulation of synaptic strength)Motor coordination (especially in cerebellar Purkinje cells)Signal transduction in the central nervous system
04

Disease associations

Neurodegenerative disease (cerebellar ataxia, including spinocerebellar ataxia, autosomal recessive type 18/SCAR18)Developmental neurological disordersMotor coordination disorders
05

Safety considerations

Loss of GRID2 function causes neurodegenerative phenotypes including cerebellar ataxia and severe developmental delayGain-of-function mutations can induce selective Purkinje cell apoptosis and lethal neurodevelopmental defectsNo drugs are currently approved or in clinical trials for direct targeting in humans; safety profile for pharmacological modulation is not established
06

Interacting drugs

9-Aminoacridine

4 more in the full profile.

07

Biomarkers

Mutations or deletions in GRID2 as a biomarker for inherited ataxias (not used for patient selection in therapy but in diagnosis/prognosis)

Beyond the preview

Go deeper on Glutamate receptor ionotropic, delta-2 subunit (GRID2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Glutamate receptor ionotropic, delta-2 subunit (GRID2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call